KRW 11870.0
(-2.63%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 78.35 Billion KRW | 63.92% |
2022 | 47.8 Billion KRW | -11.83% |
2021 | 54.21 Billion KRW | 85.22% |
2020 | 29.27 Billion KRW | 79.91% |
2019 | 16.26 Billion KRW | 1.42% |
2018 | 16.04 Billion KRW | 9.02% |
2017 | 14.71 Billion KRW | -33.58% |
2016 | 22.15 Billion KRW | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q2 | 11.7 Billion KRW | 9.92% |
2024 Q1 | 11.21 Billion KRW | 2.23% |
2023 Q1 | 39.28 Billion KRW | 151.73% |
2023 Q4 | 10.97 Billion KRW | -13.96% |
2023 Q3 | 12.75 Billion KRW | -7.19% |
2023 Q2 | 13.74 Billion KRW | -65.02% |
2023 FY | 78.35 Billion KRW | 63.92% |
2022 Q2 | 9.16 Billion KRW | -19.16% |
2022 FY | 47.8 Billion KRW | -11.83% |
2022 Q4 | 15.6 Billion KRW | 33.4% |
2022 Q3 | 11.69 Billion KRW | 27.66% |
2022 Q1 | 11.33 Billion KRW | -38.56% |
2021 Q3 | 15.07 Billion KRW | 0.0% |
2021 FY | 54.21 Billion KRW | 85.22% |
2021 Q4 | 18.44 Billion KRW | 22.35% |
2020 FY | 29.27 Billion KRW | 79.91% |
2019 FY | 16.26 Billion KRW | 1.42% |
2018 FY | 16.04 Billion KRW | 9.02% |
2017 FY | 14.71 Billion KRW | -33.58% |
2016 FY | 22.15 Billion KRW | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
InBody Co.,Ltd | 87.36 Billion KRW | 10.309% |
Curexo Inc. | 18.16 Billion KRW | -331.416% |
Seegene, Inc. | 210.08 Billion KRW | 62.701% |
i-SENS, Inc. | 91.12 Billion KRW | 14.014% |
Ray Co., Ltd. | 59.03 Billion KRW | -32.738% |
Gencurix Inc. | 12.79 Billion KRW | -512.266% |
Sugentech Inc. | 18.6 Billion KRW | -321.202% |
L&C Bio Co., Ltd | 25.86 Billion KRW | -203.002% |